Taro Pharma to pay $206M to resolve price-fixing charges
By 
Jaclyn Jaeger2020-07-24T18:28:00
Taro Pharmaceuticals will pay a $205.7 million criminal penalty to resolve charges as part of the Justice Department’s ongoing investigation into the generic pharmaceutical industry.
Related articles
-
ArticleCompliance implications of drugmakers’ $447M False Claims Act settlements
Three pharmaceutical manufacturers—Taro Pharmaceuticals USA, Sandoz, and Apotex Corp.—will pay a total of $447.2 million for alleged violations of the False Claims Act related to price-fixing.
-
Article
DOJ enforcement priorities for 2020 include antitrust
Compliance officers need to step it up in 2020; a world of heightened risk means a world of heightened regulatory oversight.
-
PremiumNavigating top risks in the insurance industry
Cyber threats, climate-related catastrophes, and disruptive technologies remain top risks reshaping the U.S. insurance industry. The question is how chief risk officers at the nation’s largest insurers are confronting them.
More from Regulatory Enforcement
-
ArticleCFTC clears deck of ‘compliance’ enforcement actions to focus on fraud
BNY, Citigroup, Santander, UBS, and two other financial institutions paid a total of $8.3M to settle separate compliance violations with the CFTC.
-
News BriefHong Kong securities regulator hits repeat offender Deutsche Bank with $3M fine
Deutsche Bank has agreed to pay a $3 million fine and has returned $5 million in fee overcharges to customers as part of a resolution with Hong Kong’s financial services regulator.
-
News BriefDOJ, SEC charge owner of Pennsylvania companies of running $770M Ponzi scheme
The majority owner of a Pennsylvania investment firm faces 100 years of prison time and huge fines for allegedly running a $770 million Ponzi scheme centered on an ATM company he also owned.